Abivax Faces Stock Drop as Cancer Cases Surface

Abivax shares fell 30% after phase 3 results for obefazimod, showing 40% improvement in remission rates but revealing cancer cases among patients.
Drug met all secondary endpoints and was generally well tolerated.
Analysts praised efficacy but raised concerns about safety issues.
CEO defended the safety profile, attributing cancer cases to unrelated factors.
Company remains a potential takeover target with a $17.5 billion bid from Eli Lilly.
Future milestones include approval by year-end, exploring IBS market, and Crohn's trial results in 2027.

Safety | Takeover | Efficacy

France | USA

Marc de Garidel | Jason Butler

2 hours ago